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commonly prescribed diagnostic tests and to know its effect on
their prescribing preferences. METHODS: This study is a
descriptive cross-sectional survey which includes data gathering
through questionnaire, retrieval, tabulating, and interpreting of
results a probability stratiﬁed random sampling of 125 TMC
physicians (regular consultants, fellows, and residents) was done.
The sample size was computed using the Lynche formula. The
physicians were stratiﬁed by specialties which include Internal
Medicine, Surgery, Pediatrics, Obstetrics and Gynecology, Oph-
thalmology, and ENT-Head and Neck Surgery and were asked
to answer a pre-tested questionnaire. Non-respondents were sent
another questionnaire for them to answer to increase response
rate. The collected data were analyzed using the percentage and
weighted average and one-way analysis of variance. Inferential
analysis was done using ANOVA. SPSS software was used for
these purposes. RESULTS: Verbal interpretation of the descrip-
tive statistics shows that all respondent physicians agree to the
statement that the prices of medications and diagnostic tests are
important factors which inﬂuence them in their practice. Fur-
thermore, the respondent physicians believe that physicians
should know the prices of medications and tests they prescribe
or order. They also consider the economic status of their patients
in their practice. However, descriptive data based on the mean
price estimates from all specialties, whether residents, fellows, or
consultants, show signiﬁcant difference in the physician per-
ceived prices of commonly prescribed and ordered medications
and diagnostic tests and the actual TMC prices of such medica-
tions and tests (p value >0.05) thereby rejecting the null hypoth-
esis saying otherwise. CONCLUSION: The Medical City
physician is not aware of the prices of medications and diag-
nostic tests he commonly prescribes or orders.
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OBJECTIVES: The use of cost-minimisation analysis, based on
a negative result from a clinical trial, has recently been ques-
tioned. Instead, it has been argued that cost-minimisation analy-
sis should only be undertaken as part of an equivalence trial,
designed to conﬁrm the absence of a meaningful difference
between treatments. The “non-inferiority” trial is becoming a
popular method of comparing a new treatment to an existing
standard as non-inferiority may be an acceptable outcome for
licensing purposes. Non-inferiority trials are designed to show
that a new treatment is no less effective than an existing treat-
ment—in reality, it may be more effective or have a similar effect
(within a margin of clinical equivalence). METHODS: In this
paper, the role of the non-inferiority trial design is critically
appraised as a vehicle for economic evaluation. RESULTS: A
number of issues are noted in relation to non-inferiority designs
that limit their usefulness for making judgements concerning the
value for money of treatments. The margin of clinical equiva-
lence is essentially arbitrary and is rendered meaningless once
costs (both in terms of resources and the health effects of any
adverse events) are considered. From an economic perspective,
acceptance of a new treatment can only be recommended if the
new treatment is both “non-inferior” in both clinical and cost
terms, however, the role of the margin of clinical equivalence
(and potentially a similar margin of cost equivalence) serves 
to cloud the comparison with the traditional concept of 
“dominance” in economic studies. CONCLUSION: The design
of trial in terms of “superiority” or “non-inferiority” does not
change the fact that separate and sequential tests of hypothesis
for costs and effects independently are to be avoided in economic
evaluation. The recommendation remains that estimation and
not hypothesis testing should be the key to interpreting cost-
effectiveness studies of new treatments.
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OBJECTIVES: In developing countries, medicines are the largest
proportion of out-of-pocket health expenses as medicines are
rarely subsidized. Medicine prices are variable and often high
and as a result medicines are frequently unaffordable for a large
proportion of the global population. In 2003, the World Health
Organisation and Health Action International (HAI) published
a manual entitled “Medicine Prices—a new approach to mea-
surement”. This innovative manual describes a method to collect
price information reliably, facilitating national and international
comparisons. METHODS: The process involves the collection of
retail price and availability data from a sample of registered
pharmacies in the public, private or “other” sector, in each of
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